Cardio-oncology & otherCohort study
Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas
- Retrospective cohort study
- multicentre
Authors' conclusion
Although ICIs demonstrate modest activity in CSTS, durable benefit was observed in a subset of patients with nonangiosarcoma, albeit with higher toxicity.
Study context
- Population
- Patients with primary cardiac soft tissue sarcomas (CSTS) treated with ICI-based regimens, 2015–2022
- Participants
- 24 patients
Main finding
As reported in the abstract
OS and PFS, advanced and metastatic CSTS (n = 22)
Median progression-free survival (PFS)
5.7 months (95% CI: 2.8-13.3 months)
Median overall survival (OS)
14.9 months (95% CI: 5.7-23.7 months)
Observational data: associations, not effects.
Further findings
months
| Outcome | Angiosarcoma | Nonangiosarcoma | P value |
|---|---|---|---|
| Median PFS and OS by histology (subgroup) · PFS | P < 0.0001 | ||
| Median PFS | 1.7 | 11 | |
| Median OS | 3.0 | 24.0 | |
| Median PFS and OS by histology (subgroup) · OS | P = 0.008 |
Objective response rate (18 with response data)
- Objective response rate
- 11.1% (n = 2 of 18)
Safety
| Outcome | Values |
|---|---|
| Treatment-related adverse events | Nonangiosarcoma 46.7% · Grade ≥3 6 (40.0%) |
Treatment-related adverse events
- Occurred exclusively in nonangiosarcoma CSTS (n = 15)
Original publication
Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas. JACC CardioOncol. Published 16 January 2024. doi:10.1016/j.jaccao.2023.11.007
Summarised from the published abstract; every number is checked against it